Sarm1 mutations are not common in ALS patients, but a careful examination of the ones that do occur by Dr. Joseph Bloom and colleagues has shown that they tend to cause Sarm1 to be constitutively active and occur more frequently in ALS patients than in the general population. This research, published in Molecular Neurodegeneration, suggests […]
Protein structure studies demonstrate how SARM1 senses cellular energy status to trigger axon degeneration
Two recent articles published by Needleman Center researchers dissect the structure of SARM1, an enzyme responsible for initiating programmed axon degeneration, and shed light on how the balance of key cellular metabolites regulate its activity. SARM1 forms an octamer in which each monomer contains an N-terminal autoinhibitory domain, domains that mediate multimerization, and a C-terminal […]
Mouse model provides hope to treat a rare form of congenital blindness
Leber congenital amaurosis (LCA) type nine is an autosomal recessive retinopathy leading to early childhood blindness caused by mutations of the NAD+ synthesis enzyme NMNAT1. In work lead by Dr. Yo Sasaki and published in the journal Elife, Needleman Center researchers demonstrated that loss of NMNAT1 leads to activation of the SARM1-mediated axon degeneration pathway in photoreceptors. Loss […]
Thomas Schwarz to give keynote speech at Inaugural Symposium
Dr. Thomas Schwarz of Harvard University will be giving the keynote address at the Inaugural Symposium for the Philip and Sima Needleman Center for Neurometabolism and Axonal Therapeutics. The symposium will be on Friday, November 15th from 1-4 p.m. in EPNEC Seminar Room B.
Kow Essuman wins 2019 O’Leary Prize
Kow Essuman, a graduate student in the Milbrandt Lab, is one of two winners of the 2019 O’Leary Prize. Yesterday Kow gave a short presentation of his research at the O’Leary Prize Competition on the Medical Campus, which was enough to convince the judges that he should win the prize. Anish Mitra, and MD/PhD candidate in the Raichle […]
Gene therapy for peripheral neuropathy successful in mice
A new paper in the Journal of Experimental Medicine details the experiments led by Dr. Stefanie Geisler in collaboration with the Milbrandt and DiAntonio labs to target SARM1 using gene therapy in mice. This is an exciting step towards possible treatments for peripheral neuropathy and other disorders involving axon breakdown.